Analysis of:
Bariatric surgery - possible treatment for type 2 diabetes mellitus (www.news-medical.net)
1. Weight loss may improve carbohydrate metabolism in patients with Type 2 DM 2. Weight loss is difficult to maintain even in these patients 3. There is more to curing type 2 DM then losing weight
Analysis of:
Sanofi aims to show there's still life in Acomplia (www.reuters.com)
Weight loss is good but the amount and time to reach goal is more important then just the weight loss potential itself
Analysis of:
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years (www.pipelinereview.com)
Long term studies of Exubera do little to reassure the product's safety. This is especially true in the face of new insulin pens that are safe, effective and makes it very easy to administer insulin.
Analysis of:
Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients (www.pipelinereview.com)
The fewer the injections, the more market share if all else is the same. We will await to see how needle size will affect LAR acceptance. My estimate is that it will absolutely not. Patients never asked what the size of the needle was prior to initiation of BYETTA bid--they just heard "weight loss and...
Analysis of:
Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA (www.pipelinereview.com)
OADs such as sulfonylureas and glitinides are being displaced today with the advent of sitagliptin for those who have coverage for this medication.
Analysis of:
AstraZeneca and Abbott Announce Selection of Next-Generation Fenofibrate (ABT-335) and Crestor Fixed-Dose Combination (pharmalive.com)
Although the pill would be effective in lowering cholesterol and triglycerides, there is no outcome data yet to show benefit comparable to Lipitor in lowering cardiovascular events. There is a report of an observational study with simvastatin, another lipid lowering drug, which shows 30% REDUCTION in cardiovascular...
Analysis of:
Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients (www.pipelinereview.com)
Liraglutide will steal some market share from the leader, exenatide, but if exenatide comes out in a once a week formulation and other similar products even less often, the market will shift again.
Analysis of:
GlaxoSmithKline updates prescribing information for Avandia in the US (www.pipelinereview.com)
-reassuring clinical data -severe PR damage
Analysis of:
Elixir Pharmaceuticals initiates final Phase III clinical study prior to NDA (www.pipelinereview.com)
Mitiglinide may have a role in specific subtypes of diabetes patients, but it thrice a day dosing in a hurdle for all but the compulsive few.